Glucagon-like peptide-1 agonists (GLP-1a) are an effective weight loss treatment for patients with obesity and heart failure.2, 3 Whether GLP-1a is associated with weight loss in patients with obesity and LVAD and/or influences LVAD parameters is unknown. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.